@inproceedings{inproceedings, title  = {{3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2015}},

 month = {{5}},

 author = {{Parker C and Vogelzang NJ and Sartor AO and Coleman RE and Skjorestad I and Fang F and Nilsson S}},

 doi = {{10.1200/jco.2015.33.15_suppl.e16102}},

 volume = {{33}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{15_suppl}},

 pages = {{e16102-e16102}},

 note = {{Accessed on 2025/10/10}}}